Matthew Dennis

Telix Pharmaceuticals has turned to the bond market to raise funds to accelerate clinical development of its theranostic portfolio, just over a month after abandoning plans to list its shares in the US.

Abiologics emerged from stealth on Tuesday with the aim of developing a new class of “programmable” medicines, dubbed Synteins, with an initial focus on oncology and immunology.

Less than two months after gaining approval of its first ever drug, Geron's chief commercial officer (CCO) Anil Kapur is set to leave the company at the end of August.

Biogen and Sage Therapeutics said Wednesday that a Phase II study of SAGE-324 for the treatment of essential tremor failed to meet its primary endpoint.

Sales of Sanofi's Dupixent soared 29.2% in the second quarter to €3.3 billion ($3.6 billion), setting a new three-month high for the product, which

AstraZeneca got a boost from sales of its two key oncology drugs Enhertu and Tagrisso in the second quarter, prompting the company to lift its guidance for the full year.

Roche on Thursday lifted its earnings guidance for the full year, which is now forecast to grow in the high-single-digit range on a constant exchange

An FDA advisory panel voted unanimously that the design of future clinical studies for perioperative regimens in resectable non-small-cell lung

European regulators on Friday recommended against approval of Eisai and Biogen's Alzheimer's disease drug Leqembi (lecanemab), deeming that the

Bristol Myers Squibb on Friday sounded an upbeat tone on the company's ability to deal with Medicare price setting that is set to come into force in the US on its topseller Eliquis.